This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor: In the June, 1961, issue of the Archives of Dermatology, G. Asboe-Hansen, M.D., Copenhagen, Denmark, reported the therapeutical essay of polymyxin B (Pfizer) in a case of generalized mastocytosis.
We tried this treatment, utilizing disyncran as a cover against histamine liberation, in a case of urticaria pigmentosa which had resisted the classical medications.
The first 2 injections (polymyxin B Pfizer, 50 mg. twice daily) were well tolerated. The third resulted in a facial pruritus. The fourth was accompanied by a light shock with dyspnea and tachycardia. The fifth dose, therefore diminished by a half (25 mg.) provoked a severe anaphylactoid shock, which necessitated the injection of adrenalin and dexamethasone (Decadron).
After each injection of polymyxin B, the cutaneous nodules became infiltrated, and the appearance of numerous additional nodules was noted.
This observation showed clinical evidence of the degranulating effect of polymyxin B on the human pathologic mast
Lucien Craps. DANGER OF POLYMYXIN B. Arch Dermatol. 1963;87(1):2. doi:10.1001/archderm.1963.01590130008002
* * Maintenance Notice * *
Maintenance will be performed from 11:00pm CT December 16, 2017 to 4:00pm CT December 17. Please be advised that your site/services may be periodically unavailable during this maintenance window.